8-K - IDEXX Laboratories, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

IDEXX Laboratories, Inc. announced that Nimrata Hunt, PhD, Executive Vice President, Global Strategy and Commercial, will cease her role effective April 13, 2026, and provide advisory services until July 13, 2026, under a Separation Agreement providing $2,286,000 in total separation benefits due to position elimination.

Key Takeaways

1Nimrata Hunt, PhD, to cease role as Executive Vice President, Global Strategy and Commercial on April 13, 2026

2Advisory services as Special Advisor until Final Employment Date of July 13, 2026

3Separation benefits total $2,286,000 including $1,230,000 salary continuation for 104 weeks and $984,000 target bonus

4Additional benefits: $50,000 COBRA premiums for 78 weeks, $10,000 transition assistance, $12,000 max tax/financial planning

5Position eliminated, deemed termination without cause

6Unvested stock awards forfeit as of July 13, 2026; vested options remain exercisable per agreements

Current Report Details

Event Type

Management Change

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On March 24,

Management Change

$1.2M$984.0K$50.0K$10.0K

9.01

Financial Statements and Exhibits. (d) Exhibits 10.1 Separation Agreement by and between Nimrata Hunt, PhD, and IDEXX Laboratories, Inc., dated March 24, 2026.

Exhibits Only

Executive & Director Changes

Nimrata Hunt, PhD

Executive Vice President, Global Strategy and Commercial

Cease role / Separation

Effective: 2026-04-13

Position eliminated; termination without cause

Exhibits (2)

10.1

EXHIBIT 10.1

8-K

FORM 8-K